Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Remibrutinib; Drug: Teriflunomide
Sponsor: Novartis Pharmaceuticals
Recruiting

Author:

Published July 16, 2022

Categorized as Clinical Trials, Multiple Sclerosis (MS)

Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

About the blog

Health Information Technology System News and Healthcare Advances. Also Learn More about the Field of Health Data Scientists

Please leave this field empty

Health Data Scientist

Don’t miss these tips!

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

New Product Review

Evaluate New Health Applications. Be the first to decide. Your opinion matters.

Survey